{"filing":{"accession_number":"0001104659-26-095218","cik":"0001889109","ticker":"BLTE","company_name":"BELITE BIO, INC","form":"6-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"tm2623018d1_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1889109/000110465926095218/tm2623018d1_6k.htm"},"events":[{"id":27401,"run_id":24969,"accession_number":"0001104659-26-095218","anchor_item_number":"EX-99.1","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This exhibit is a press release announcing Belite Bio's unaudited second quarter 2026 financial results, including detailed income statements, balance sheet data, and operating metrics. The document explicitly states \"Belite Bio Reports Unaudited Second Quarter 2026 Financial Results\" and includes comprehensive financial tables showing net loss of $28.4 million for Q2 2026 and $55.4 million for the six-month period. This is a discrete earnings announcement, not a periodic financial report filing, and is material as it discloses significant operating losses and cash burn relevant to investor assessment.","company_name":"BELITE BIO, INC","ticker":"BLTE","filing_date":"2026-08-12","form":"6-K","submitted_at":null,"items":[{"id":28925,"accession_number":"0001104659-26-095218","item_number":"EX-99.1","item_title":"tm2623018d1_ex99-1.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This exhibit is a press release announcing Belite Bio's unaudited second quarter 2026 financial results, including detailed income statements, balance sheet data, and operating metrics. The document explicitly states \"Belite Bio Reports Unaudited Second Quarter 2026 Financial Results\" and includes comprehensive financial tables showing net loss of $28.4 million for Q2 2026 and $55.4 million for the six-month period. This is a discrete earnings announcement, not a periodic financial report filing, and is material as it discloses significant operating losses and cash burn relevant to investor assessment.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-13T10:07:43.673455+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28925,"accession_number":"0001104659-26-095218","item_number":"EX-99.1","item_title":"tm2623018d1_ex99-1.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This exhibit is a press release announcing Belite Bio's unaudited second quarter 2026 financial results, including detailed income statements, balance sheet data, and operating metrics. The document explicitly states \"Belite Bio Reports Unaudited Second Quarter 2026 Financial Results\" and includes comprehensive financial tables showing net loss of $28.4 million for Q2 2026 and $55.4 million for the six-month period. This is a discrete earnings announcement, not a periodic financial report filing, and is material as it discloses significant operating losses and cash burn relevant to investor assessment.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-13T10:07:43.673455+00:00","company_name":"BELITE BIO, INC","ticker":"BLTE","filing_date":"2026-08-12"}]}